JP2007511582A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007511582A5 JP2007511582A5 JP2006540446A JP2006540446A JP2007511582A5 JP 2007511582 A5 JP2007511582 A5 JP 2007511582A5 JP 2006540446 A JP2006540446 A JP 2006540446A JP 2006540446 A JP2006540446 A JP 2006540446A JP 2007511582 A5 JP2007511582 A5 JP 2007511582A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- pharmaceutical composition
- alkyl
- composition according
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 150000002148 esters Chemical class 0.000 claims 5
- 208000017169 kidney disease Diseases 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- -1 dioxolanylmethyl group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical group C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims 1
- JBRHCMAUNJIELM-UHFFFAOYSA-N 2-(1-benzazepin-1-yl)-2-oxoacetic acid Chemical compound OC(=O)C(=O)N1C=CC=CC2=CC=CC=C12 JBRHCMAUNJIELM-UHFFFAOYSA-N 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000029142 excretion Effects 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000001474 proteinuria Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03104264.1 | 2003-11-18 | ||
| EP03104264 | 2003-11-18 | ||
| PCT/EP2004/052963 WO2005049035A1 (en) | 2003-11-18 | 2004-11-15 | Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007511582A JP2007511582A (ja) | 2007-05-10 |
| JP2007511582A5 true JP2007511582A5 (https=) | 2007-11-22 |
| JP4824573B2 JP4824573B2 (ja) | 2011-11-30 |
Family
ID=34610099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006540446A Expired - Fee Related JP4824573B2 (ja) | 2003-11-18 | 2004-11-15 | 腎不全、腎疾患または腎障害、特に糖尿病患者におけるこれらの治療のための医薬組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7273860B2 (https=) |
| EP (1) | EP1687006B1 (https=) |
| JP (1) | JP4824573B2 (https=) |
| CN (1) | CN100566719C (https=) |
| AR (1) | AR046454A1 (https=) |
| AT (1) | ATE378053T1 (https=) |
| AU (1) | AU2004290925B2 (https=) |
| BR (1) | BRPI0416706A (https=) |
| CA (1) | CA2545802A1 (https=) |
| DE (1) | DE602004010172T2 (https=) |
| ES (1) | ES2297536T3 (https=) |
| MX (1) | MXPA06005547A (https=) |
| PL (1) | PL1687006T3 (https=) |
| TW (1) | TWI344366B (https=) |
| WO (1) | WO2005049035A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60040089D1 (de) * | 1999-11-19 | 2008-10-09 | Solvay Pharm Bv | Menschliches homolog aus der familie der metalloproteasen |
| AR049401A1 (es) | 2004-06-18 | 2006-07-26 | Novartis Ag | Aza-biciclononanos |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| US20060159748A1 (en) * | 2004-12-23 | 2006-07-20 | Rajesh Jain | Oral immediate release formulation of a poorly water-soluble active substance |
| TWI741240B (zh) * | 2017-12-11 | 2021-10-01 | 日商埃塔斯製藥股份有限公司 | 含有1,4-苯并硫氮呯-1-氧化物衍生物之光學異構物之腎功能障礙的改善藥 |
| PL424453A1 (pl) * | 2018-01-31 | 2019-08-12 | Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością | Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) |
| CN112292125B (zh) * | 2018-06-22 | 2023-10-31 | 西奈克制药有限公司 | 蛋白尿的治疗 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0254032A3 (en) * | 1986-06-20 | 1990-09-05 | Schering Corporation | Neutral metalloendopeptidase inhibitors in the treatment of hypertension |
| DE19510566A1 (de) * | 1995-03-23 | 1996-09-26 | Kali Chemie Pharma Gmbh | Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE19638020A1 (de) * | 1996-09-18 | 1998-03-19 | Solvay Pharm Gmbh | Die gastrointestinale Durchblutung fördernde Arzneimittel |
| DE19906310A1 (de) * | 1999-02-16 | 2000-08-17 | Solvay Pharm Gmbh | Arzneimittel zur Behandlung von Bluthochdruck |
| DE19932555A1 (de) * | 1999-07-13 | 2001-01-18 | Solvay Pharm Gmbh | Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen |
| SE9903028D0 (sv) * | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
| RU2303041C2 (ru) * | 2002-01-16 | 2007-07-20 | Солвей Фармасьютикалс Б.В. | Твердые соли бензазепиновых соединений и их применение при получении фармацевтических соединений |
| PE20040468A1 (es) * | 2002-05-17 | 2004-09-14 | Novartis Ag | Combinacion de compuestos organicos |
-
2004
- 2004-11-15 JP JP2006540446A patent/JP4824573B2/ja not_active Expired - Fee Related
- 2004-11-15 TW TW093134862A patent/TWI344366B/zh not_active IP Right Cessation
- 2004-11-15 CN CNB2004800330307A patent/CN100566719C/zh not_active Expired - Fee Related
- 2004-11-15 CA CA002545802A patent/CA2545802A1/en not_active Abandoned
- 2004-11-15 AT AT04818828T patent/ATE378053T1/de not_active IP Right Cessation
- 2004-11-15 ES ES04818828T patent/ES2297536T3/es not_active Expired - Lifetime
- 2004-11-15 MX MXPA06005547A patent/MXPA06005547A/es active IP Right Grant
- 2004-11-15 WO PCT/EP2004/052963 patent/WO2005049035A1/en not_active Ceased
- 2004-11-15 AR ARP040104208A patent/AR046454A1/es not_active Application Discontinuation
- 2004-11-15 PL PL04818828T patent/PL1687006T3/pl unknown
- 2004-11-15 EP EP04818828A patent/EP1687006B1/en not_active Expired - Lifetime
- 2004-11-15 BR BRPI0416706-6A patent/BRPI0416706A/pt not_active IP Right Cessation
- 2004-11-15 DE DE602004010172T patent/DE602004010172T2/de not_active Expired - Lifetime
- 2004-11-15 AU AU2004290925A patent/AU2004290925B2/en not_active Ceased
- 2004-11-16 US US10/988,847 patent/US7273860B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gredic et al. | Pulmonary hypertension in chronic obstructive pulmonary disease | |
| Nicholls et al. | ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies | |
| ES2645726T3 (es) | Formulación farmacéutica en forma de comprimidos bicapa que comprenden inhibidor de la HMG-CoA reductasa e irbesartán | |
| RU2012117786A (ru) | Новое производное фенола | |
| CN1846699A (zh) | 1－(取代苯基)－5－甲基－2－(1h) 吡啶酮(i)化合物用于制备抗除肾间质纤维化外其他器官纤维化或组织纤维化药物的应用 | |
| JP2007508360A5 (https=) | ||
| JP2010511631A5 (https=) | ||
| JP2009519965A5 (https=) | ||
| JP2011527332A5 (https=) | ||
| JP2010523682A5 (https=) | ||
| JP2004522714A5 (https=) | ||
| JP2012533546A5 (https=) | ||
| JP2005526696A5 (https=) | ||
| RU2008151414A (ru) | Соединение для лечения метаболических расстройств | |
| JP2008531520A5 (https=) | ||
| JP2010031018A5 (https=) | ||
| JP2007522135A5 (https=) | ||
| JP2009535393A5 (https=) | ||
| JP2015164972A5 (https=) | ||
| JP2012504608A5 (https=) | ||
| JP2009528275A5 (https=) | ||
| JP2011527675A5 (https=) | ||
| EP3823628A1 (en) | <smallcaps/>? ? ?s? ? ? ? ?certain (2)- <ns1:i>n</ns1:i>?-[(1 <ns2:i>s</ns2:i>?)-1-cyano-2-phenylethyl]-1,4- oxazepane-2-carboxamides for treating inflammatory bowel disease | |
| JP2013531070A5 (https=) | ||
| RU2006134022A (ru) | Производные индазола и содержащие их фармацевтические композиции |